LakeShore Biopharma (LSB) Competitors $1.06 -0.05 (-4.50%) Closing price 07/15/2025 04:00 PM EasternExtended Trading$1.05 -0.01 (-0.94%) As of 07:10 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisChartCompetitorsHeadlinesOwnershipSEC FilingsShort InterestTrendsBuy This Stock LSB vs. XLO, CGTX, ATHE, AKTX, LVTX, TELO, RANI, RNTX, CLNN, and KALAShould you be buying LakeShore Biopharma stock or one of its competitors? The main competitors of LakeShore Biopharma include Xilio Therapeutics (XLO), Cognition Therapeutics (CGTX), Alterity Therapeutics (ATHE), Akari Therapeutics (AKTX), LAVA Therapeutics (LVTX), Telomir Pharmaceuticals (TELO), Rani Therapeutics (RANI), Rein Therapeutics (RNTX), Clene (CLNN), and KALA BIO (KALA). These companies are all part of the "pharmaceutical products" industry. LakeShore Biopharma vs. Its Competitors Xilio Therapeutics Cognition Therapeutics Alterity Therapeutics Akari Therapeutics LAVA Therapeutics Telomir Pharmaceuticals Rani Therapeutics Rein Therapeutics Clene KALA BIO LakeShore Biopharma (NASDAQ:LSB) and Xilio Therapeutics (NASDAQ:XLO) are both small-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their profitability, risk, institutional ownership, media sentiment, earnings, valuation, dividends and analyst recommendations. Is LSB or XLO more profitable? LakeShore Biopharma has a net margin of 0.00% compared to Xilio Therapeutics' net margin of -585.54%. LakeShore Biopharma's return on equity of 0.00% beat Xilio Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets LakeShore BiopharmaN/A N/A N/A Xilio Therapeutics -585.54%-262.69%-64.01% Does the media favor LSB or XLO? In the previous week, LakeShore Biopharma had 1 more articles in the media than Xilio Therapeutics. MarketBeat recorded 2 mentions for LakeShore Biopharma and 1 mentions for Xilio Therapeutics. Xilio Therapeutics' average media sentiment score of 1.89 beat LakeShore Biopharma's score of 0.84 indicating that Xilio Therapeutics is being referred to more favorably in the news media. Company Overall Sentiment LakeShore Biopharma Positive Xilio Therapeutics Very Positive Which has more risk & volatility, LSB or XLO? LakeShore Biopharma has a beta of 0.58, suggesting that its share price is 42% less volatile than the S&P 500. Comparatively, Xilio Therapeutics has a beta of -0.15, suggesting that its share price is 115% less volatile than the S&P 500. Which has preferable valuation & earnings, LSB or XLO? Xilio Therapeutics has lower revenue, but higher earnings than LakeShore Biopharma. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioLakeShore Biopharma$80.82MN/A-$61.09MN/AN/AXilio Therapeutics$6.34M5.82-$58.24M-$0.84-0.85 Do insiders and institutionals have more ownership in LSB or XLO? 52.6% of LakeShore Biopharma shares are held by institutional investors. Comparatively, 54.3% of Xilio Therapeutics shares are held by institutional investors. 6.3% of Xilio Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth. Do analysts rate LSB or XLO? Xilio Therapeutics has a consensus price target of $4.00, suggesting a potential upside of 460.93%. Given Xilio Therapeutics' stronger consensus rating and higher probable upside, analysts plainly believe Xilio Therapeutics is more favorable than LakeShore Biopharma.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score LakeShore Biopharma 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00Xilio Therapeutics 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 3.00 SummaryXilio Therapeutics beats LakeShore Biopharma on 7 of the 13 factors compared between the two stocks. Get LakeShore Biopharma News Delivered to You Automatically Sign up to receive the latest news and ratings for LSB and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding LSB and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart LSB vs. The Competition Export to ExcelMetricLakeShore BiopharmaMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$10.33M$2.96B$5.61B$9.29BDividend YieldN/A2.43%4.23%4.03%P/E RatioN/A20.2228.5419.58Price / SalesN/A299.17429.2495.01Price / CashN/A43.1536.0257.93Price / Book0.127.568.145.54Net Income-$61.09M-$55.11M$3.24B$257.73M7 Day Performance-10.92%3.81%0.18%-0.08%1 Month Performance6.00%11.60%5.96%8.09%1 Year Performance-77.87%-2.11%26.24%13.02% LakeShore Biopharma Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)LSBLakeShore Biopharma0.7294 of 5 stars$1.06-4.5%N/A-76.1%$10.33M$80.82M0.00773Gap DownXLOXilio Therapeutics2.8935 of 5 stars$0.71+1.6%$4.00+463.2%-29.4%$36.77M$6.34M-0.8570CGTXCognition Therapeutics2.9299 of 5 stars$0.59+1.7%$2.83+381.5%-70.4%$36.48MN/A-0.8020High Trading VolumeATHEAlterity Therapeutics2.1591 of 5 stars$4.11+6.2%$12.00+192.0%+122.4%$36.46MN/A0.0010AKTXAkari Therapeutics0.8618 of 5 stars$1.12+0.9%N/A-70.9%$36.04MN/A0.009LVTXLAVA Therapeutics2.197 of 5 stars$1.36+2.8%$3.17+133.4%-22.2%$35.70M$11.98M-1.3060Positive NewsGap DownTELOTelomir Pharmaceuticals3.5454 of 5 stars$1.17+1.7%$15.00+1,182.1%-72.7%$34.82MN/A-2.791Positive NewsRANIRani Therapeutics1.9902 of 5 stars$0.60+12.1%$7.33+1,119.4%-89.2%$34.57M$1.20M-0.61110News CoverageGap DownRNTXRein TherapeuticsN/A$1.55+0.6%N/AN/A$34.33MN/A-0.549CLNNClene3.5681 of 5 stars$3.80-1.8%$40.00+952.6%-26.0%$34.12M$340K-0.94100KALAKALA BIO3.8896 of 5 stars$5.16-2.3%$13.50+161.6%-28.1%$33.28M$3.89M-0.6330 Related Companies and Tools Related Companies Xilio Therapeutics Competitors Cognition Therapeutics Competitors Alterity Therapeutics Competitors Akari Therapeutics Competitors LAVA Therapeutics Competitors Telomir Pharmaceuticals Competitors Rani Therapeutics Competitors Rein Therapeutics Competitors Clene Competitors KALA BIO Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:LSB) was last updated on 7/16/2025 by MarketBeat.com Staff From Our PartnersMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredWhy Elon is funding the “Quantum Power Grid”Elon knows the future isn’t about smarter AI — it’s about powering it. And this new technology is quietly b...True Market Insiders | SponsoredSpecial gold investment soars 2,300% ... 5,090% ... 9,850%In my 54 years as an investor, I’ve seen my share of gold bull markets. But nothing comes close to the rall...Weiss Ratings | SponsoredWhich Gold Miner Trades at 30% of NAV? The One Buffett WantsSome of the world’s best gold developers are trading at just 30% of NAV — like buying a dollar for 30 cents. ...Golden Portfolio | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredThe Trump Dump is starting; Get out of stocks now?The first 365 days of the Trump presidency… Will be the best time to get rich in American history.Paradigm Press | SponsoredPost-Halving = Profit Season (Here’s How to Win It)It happens like clockwork. Every four years, the crypto market enters a new phase — and for those who know how...Crypto Swap Profits | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding LakeShore Biopharma Co., Ltd. Please log in to your account or sign up in order to add this asset to your watchlist. Share LakeShore Biopharma With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
